Avellino Labs adds technologist to executive advisory committee

William F. Stasior has been added to the executive advisory committee for Avellino Labs, where he will consult on genetic data management infrastructure, according to a press release.

Stasior previously led the team responsible for Siri at Apple and was a member of Amazon’s senior executive team, the release said.

“Bill brings tremendous knowledge and skill in developing platforms for managing complex data systems, and we are extremely pleased to work with him as we build out our robust genetic services profile,” Gene Lee, Avellino Labs chairman of the board, said in the release. “Ultimately, we hope to derive industry and life-changing findings through the analysis of genetic data via artificial intelligence engines and applications.”

Avellino Labs has tested more than 720,000 patients for various forms of corneal dystrophies and is preparing a global rollout of its latest diagnostic innovation.

“Delivering on the potential of genetic data to address a broad array of health issues is an exciting opportunity,” Stasior said in the release. “Avellino Labs has built a foundation for genetic diagnosis and therapeutics in ophthalmology and, with a strong data platform, we can rapidly expand the company’s capabilities into other areas of disease research and health care.”

William F. Stasior has been added to the executive advisory committee for Avellino Labs, where he will consult on genetic data management infrastructure, according to a press release.

Stasior previously led the team responsible for Siri at Apple and was a member of Amazon’s senior executive team, the release said.

“Bill brings tremendous knowledge and skill in developing platforms for managing complex data systems, and we are extremely pleased to work with him as we build out our robust genetic services profile,” Gene Lee, Avellino Labs chairman of the board, said in the release. “Ultimately, we hope to derive industry and life-changing findings through the analysis of genetic data via artificial intelligence engines and applications.”

Avellino Labs has tested more than 720,000 patients for various forms of corneal dystrophies and is preparing a global rollout of its latest diagnostic innovation.

“Delivering on the potential of genetic data to address a broad array of health issues is an exciting opportunity,” Stasior said in the release. “Avellino Labs has built a foundation for genetic diagnosis and therapeutics in ophthalmology and, with a strong data platform, we can rapidly expand the company’s capabilities into other areas of disease research and health care.”